CARDURA-1 TAB 1MG 1 MG
DOXAZOSIN (DOXAZOSIN MESYLATE) : 1 MG · DIN 01958100 · PFIZER CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is CARDURA-1 TAB 1MG?
CARDURA-1 TAB 1MG 1 MG contains DOXAZOSIN (DOXAZOSIN MESYLATE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 01958100, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Sep-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CARDURA-1 TAB 1MG used for?
Treatment of mild to moderate essential hypertension (sole or combination therapy) and symptomatic treatment of benign prostatic hyperplasia (BPH).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01958100 |
|---|---|
| Brand name | CARDURA-1 TAB 1MG |
| Generic / active ingredient | DOXAZOSIN (DOXAZOSIN MESYLATE) : 1 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C02CA04 DOXAZOSIN |
| AHFS class | 24:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Sep-2018 |
| Original market date | 1992-12-31 00:00:00 |
How is it administered?
Administered once daily (morning or evening). Initial dose is 1 mg to minimize syncope/hypotension, then titrated slowly based on response. Maintenance doses up to 8 mg/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text.
How is it supplied?
Not explicitly detailed in provided text (mentions 1, 2, and 4 mg tablets).
Contraindications
Hypersensitivity to doxazosin, other quinazolines, or any ingredient; rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Warnings and precautions
Syncope and 'First Dose' effect; orthostatic hypotension; priapism; rare hematological events (leukopenia, neutropenia); peripheral edema; Intraoperative Floppy Iris Syndrome (IFIS) during surgery.
What can be used instead?
Other Canadian products sharing ATC code C02CA04 DOXAZOSIN. 9 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DOXAZOSIN | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02240588 |
| APO-DOXAZOSIN | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02240589 |
| APO-DOXAZOSIN | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02240590 |
| JAMP-DOXAZOSIN | 1 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02489937 |
| JAMP-DOXAZOSIN | 2 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02489945 |
| JAMP-DOXAZOSIN | 4 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02489953 |
| TEVA-DOXAZOSIN | 1 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02242728 |
| TEVA-DOXAZOSIN | 2 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02242729 |
| TEVA-DOXAZOSIN | 4 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02242730 |
| CARDURA-1,2,AND 4 | 4 MG | KIT ; TABLET | ASTRAZENECA CANADA INC | CANCELLED PRE MARKET | DIN 02231762 |
Who else supplies DOXAZOSIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOXAZOSIN appears in 79 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.